Literature DB >> 22771871

Comparison of shock-first strategy and cardiopulmonary resuscitation-first strategy in a porcine model of prolonged cardiac arrest.

Zhi-Jun Guo1, Chun-Sheng Li, Wen-Peng Yin, Xiao-Min Hou, Wei Gu, Da Zhang.   

Abstract

OBJECTIVE: The choice of a shock-first or a cardiopulmonary resuscitation (CPR)-first strategy in the treatment of prolonged cardiac arrest (CA) is still controversial. The purpose of this study was to compare the effects of these strategies on oxygen metabolism and resuscitation outcomes in a porcine model of 8min CA.
METHODS: Ventricular fibrillation (VF) was electrically induced. After 8min of untreated VF, 24 male inbred Wu-Zhi-Shan miniature pigs were randomized to receive either defibrillation first (ID group) or chest compression first (IC group). In the ID group, a shock was delivered immediately. If the defibrillation attempt failed to attain restoration of spontaneous circulation (ROSC), manual chest compressions were rapidly initiated at a rate of 100compressionsmin(-1), and the compression-to-ventilation ratio was 30:2. If VF persisted after five cycles of CPR, a second defibrillation attempt was made. In the IC group, chest compressions were delivered first, followed by a shock.
RESULTS: Hemodynamic variables, the VF waveform and blood gas analysis outcomes were recorded. Oxygen metabolism parameters and the amplitude spectrum area (AMSA) of the VF waveform were computed. There were no significant differences in the rate of ROSC and 24h survival between two groups. The ID group had lower lactic acid levels, higher cardiac output, better oxygen consumption and better oxygen extraction ratio at 4 and 6h after ROSC than the IC group.
CONCLUSIONS: In a porcine model of prolonged CA, the choice of a shock-first or CPR-first strategy did not affect the rate of ROSC and 24h survival, but the shock-first strategy might result in better hemodynamic status and better oxygen metabolism than the CPR-first strategy at the first 6h after ROSC.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22771871     DOI: 10.1016/j.resuscitation.2012.06.021

Source DB:  PubMed          Journal:  Resuscitation        ISSN: 0300-9572            Impact factor:   5.262


  7 in total

Review 1.  Therapeutic effects of Shenfu Injection on post-cardiac arrest syndrome.

Authors:  Zhi-jun Guo; Chun-sheng Li
Journal:  Chin J Integr Med       Date:  2013-08-24       Impact factor: 1.978

2.  What is more important: defibrillation or compression?

Authors:  Wei Gu; Chun-Sheng Li
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

3.  Comparison of Shenfu Injection () and epinephrine on catecholamine levels in a porcine model of prolonged cardiac arrest.

Authors:  Da Zhang; Chun-Sheng Li; Zhi-Jun Guo; Wen-Peng Yin; Xiao-Min Hou
Journal:  Chin J Integr Med       Date:  2015-03-06       Impact factor: 1.978

4.  Shen-Fu Injection () alleviates post-resuscitation myocardial dysfunction by up-regulating expression of sarcoplasmic reticulum Ca(2+)-ATPase.

Authors:  Zhi-Jun Guo; Cai-Jun Wu; Chun-Sheng Li
Journal:  Chin J Integr Med       Date:  2015-08-11       Impact factor: 1.978

5.  Risk factor analyses for the return of spontaneous circulation in the asphyxiation cardiac arrest porcine model.

Authors:  Cai-Jun Wu; Zhi-Jun Guo; Chun-Sheng Li; Yi Zhang; Jun Yang
Journal:  Chin Med J (Engl)       Date:  2015-04-20       Impact factor: 2.628

6.  Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation.

Authors:  Guoxing Wang; Qian Zhang; Wei Yuan; Junyuan Wu; Chunsheng Li
Journal:  Int J Mol Med       Date:  2016-09-15       Impact factor: 4.101

7.  Sildenafil Protects against Myocardial Ischemia-Reperfusion Injury Following Cardiac Arrest in a Porcine Model: Possible Role of the Renin-Angiotensin System.

Authors:  Guoxing Wang; Qian Zhang; Wei Yuan; Junyuan Wu; Chunsheng Li
Journal:  Int J Mol Sci       Date:  2015-11-12       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.